Moderna, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Moderna, Inc. (MRNA) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 381.33 million shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-26.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-02-26
- Moderna, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 396.81M shares, a 18.65% increase year-over-year.
- Moderna, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 394.68M shares, a 19.32% increase year-over-year.
- Moderna, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 380.53M shares, a 15.60% increase year-over-year.
- Moderna, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-03-31 was 353.11M shares, a 7.39% increase year-over-year.
- Moderna, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 381.33M shares, a 15.28% increase from fiscal 2019.
- Moderna, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 330.80M shares, a 307.82% increase from fiscal 2018.
- Moderna, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 81.11M shares, a 25.76% increase from fiscal 2017.
- Moderna, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 64.50M shares, a 6.17% increase from fiscal 2016.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2020-12-31 | 396.81M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | 395.75M shares derived: average of 2 quarters · filed 2021-02-26 | 390.67M shares derived: average of 3 quarters · filed 2021-02-26 | 381.33M shares 10-K · filed 2021-02-26 |
| 2020-09-30 | 394.68M shares 10-Q · filed 2020-10-30 | 387.61M shares derived: average of 2 quarters · filed 2020-10-30 | 376.17M shares 10-Q · filed 2020-10-30 | 365.69M shares derived: average of 4 quarters · filed 2021-02-26 |
| 2020-06-30 | 380.53M shares 10-Q · filed 2020-08-06 | 366.82M shares 10-Q · filed 2020-08-06 | 356.02M shares derived: average of 3 quarters · filed 2021-02-26 | 349.71M shares derived: average of 4 quarters · filed 2021-02-26 |
| 2020-03-31 | 353.11M shares 10-Q · filed 2020-05-07 | 343.77M shares derived: average of 2 quarters · filed 2021-02-26 | 339.44M shares derived: average of 3 quarters · filed 2021-02-26 | 336.87M shares derived: average of 4 quarters · filed 2021-02-26 |
| 2019-12-31 | 334.43M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | 332.60M shares derived: average of 2 quarters · filed 2021-02-26 | 331.46M shares derived: average of 3 quarters · filed 2021-02-26 | 330.80M shares 10-K · filed 2021-02-26 |
| 2019-09-30 | 330.77M shares 10-Q · filed 2020-10-30 | 329.97M shares derived: average of 2 quarters · filed 2020-10-30 | 329.59M shares 10-Q · filed 2020-10-30 | 278.89M shares derived: average of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | 329.18M shares 10-Q · filed 2020-08-06 | 328.99M shares 10-Q · filed 2020-08-06 | 261.59M shares derived: average of 3 quarters · filed 2021-02-26 | 212.77M shares derived: average of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | 328.81M shares 10-Q · filed 2020-05-07 | 227.80M shares derived: average of 2 quarters · filed 2021-02-26 | 173.96M shares derived: average of 3 quarters · filed 2021-02-26 | 146.96M shares derived: average of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | 126.79M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | 96.54M shares derived: average of 2 quarters · filed 2021-02-26 | 86.34M shares derived: average of 3 quarters · filed 2021-02-26 | 81.11M shares 10-K · filed 2021-02-26 |
| 2018-09-30 | 66.28M shares 10-Q · filed 2019-11-06 | 66.11M shares derived: average of 2 quarters · filed 2019-11-06 | 65.89M shares 10-Q · filed 2019-11-06 | |
| 2018-06-30 | 65.94M shares 10-Q · filed 2019-08-08 | 65.69M shares 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | 65.43M shares 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | 64.50M shares 10-K · filed 2020-02-27 | |||
| 2016-12-31 | 60.75M shares 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |